Compare ELLO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ELLO | CBIO |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | Israel | United States |
| Employees | N/A | 44 |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.8M | 557.8M |
| IPO Year | 1998 | N/A |
| Metric | ELLO | CBIO |
|---|---|---|
| Price | $25.00 | $19.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 3.5K | ★ 242.5K |
| Earning Date | 03-31-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.21 | $8.72 |
| 52 Week High | $30.34 | $20.58 |
| Indicator | ELLO | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 72.98 |
| Support Level | $24.40 | $10.89 |
| Resistance Level | $25.70 | $20.58 |
| Average True Range (ATR) | 0.46 | 1.87 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 54.84 | 94.55 |
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.